Three research groups from the Inst. for Cancer Res. involved in projects receiving FUGE grants
The Board of FUGE (Functional Genomics in Norway) decided in a meeting in June to grant a total sum of NOK 118 mill to support research projects within the field of functional genomics. A large number of very good applications competed sharply about project support in this round. Of the 126 applications received within the closing date Dec 1st 2005, as many as 60 were in the "A" category, meaning "very good projects worthy of support". In the end, only 18 projects were selected. They run over a period of three years, and will receive between 5 and 11 mill. NOK each. Researchers from the Institute for Cancer research are involved in three of these projects.
From major journals, first or last author from the Institute for Cancer Research
Kong W, He L, Zhu J, Brück O, Porkka K, Heckman CA, Zhu S, Aittokallio T(2022) An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia Leukemia(in press) DOI 10.1038/s41375-022-01662-6, PubMed 35945345
Berg J, Halvorsen AR, Bengtson MB, Lindberg M, Halvorsen B, Aukrust P, Helland Å, Ueland T(2022) Circulating T Cell Activation and Exhaustion Markers Are Associated With Radiation Pneumonitis and Poor Survival in Non-Small-Cell Lung Cancer Front Immunol, 13, 875152 DOI 10.3389/fimmu.2022.875152, PubMed 35911763
Skanland SS, Brown JR(2022) PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here? Haematologica(in press) DOI 10.3324/haematol.2022.281266, PubMed 35899388
Venizelos A, Engebrethsen C, Deng W, Geisler J, Geisler S, Iversen GT, Aas T, Aase HS, Seyedzadeh M, Steinskog ES, Myklebost O, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Lønning PE, Knappskog S, Eikesdal HP(2022) Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy Genome Med, 14(1), 86 DOI 10.1186/s13073-022-01090-2, PubMed 35948919
Kong W, He L, Zhu J, Brück O, Porkka K, Heckman CA, Zhu S, Aittokallio T(2022) An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia Leukemia(in press) DOI 10.1038/s41375-022-01662-6, PubMed 35945345
Ree AH, Mælandsmo GM, Flatmark K, Russnes HG, Gómez Castañeda M, Aas E(2022) Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study Acta Oncol, 1-8(in press) DOI 10.1080/0284186X.2022.2098053, PubMed 35943168